Claim 70% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
The latest update is out from Verrica Pharmaceuticals ( (VRCA) ).
On December 26, 2025, Verrica Pharmaceuticals Inc. appointed Charles Frantzreb, a partner at therapeutics-focused investment firm Caligan Partners and a physician by training, to its Board of Directors as a Class III director, with a term running through the 2027 annual meeting of stockholders; his appointment stems from a securities purchase agreement with institutional investors and reflects Caligan’s direct governance role in the company. Separately, on December 23, 2025, the board’s Compensation Committee approved equity awards under Verrica’s 2018 Equity Incentive Plan, including a large, performance- and stock-price-contingent stock option grant to President and CEO Jayson Rieger and fully vested restricted stock units to Interim CFO John Kirby, moves aimed at strengthening long-term management incentives, addressing comparatively low insider ownership versus peers, and supporting retention amid recent financing activities and an expanded share base.
The most recent analyst rating on (VRCA) stock is a Buy with a $17.00 price target. To see the full list of analyst forecasts on Verrica Pharmaceuticals stock, see the VRCA Stock Forecast page.
Spark’s Take on VRCA Stock
According to Spark, TipRanks’ AI Analyst, VRCA is a Neutral.
Verrica Pharmaceuticals’ overall stock score is primarily impacted by its poor financial performance, characterized by declining revenues and negative equity. Despite positive technical indicators and strategic corporate events, the company’s valuation remains a concern due to ongoing losses. The earnings call provided some optimism with growth in product dispensations and regulatory progress, but financial instability remains a significant risk.
To see Spark’s full report on VRCA stock, click here.
More about Verrica Pharmaceuticals
Verrica Pharmaceuticals Inc. operates in the biopharmaceutical industry, focusing on the development and commercialization of dermatology and therapeutics-related treatments, with its investor base including specialized healthcare and therapeutics-focused funds such as Caligan Partners LP.
Average Trading Volume: 291,945
Technical Sentiment Signal: Sell
Current Market Cap: $77.44M
Learn more about VRCA stock on TipRanks’ Stock Analysis page.